Innate Pharma (IPHA) Operating Margin (2021 - 2024)

Innate Pharma (IPHA) has reported Operating Margin for 3 consecutive years, with 317.29% the latest figure, recorded in Q2 2024.

• Quarterly Operating Margin fell 31617.0% year-over-year to 317.29% in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 0.2% (down 4.0% YoY) and the FY2025 annual result came in at 599.76%, down 34343.0% from the prior year.
• Operating Margin eased to 317.29% in Q2 2024 per IPHA's latest filing, from 1.13% in the prior quarter.
• Over the last five years, Operating Margin for IPHA reached as high as 1.13% in Q2 2023 and fell as low as 394.86% in Q4 2021.
• A 3-year average of 237.76% and a median of 317.29% in 2024 frame the typical range for Operating Margin.
• The largest YoY upside for Operating Margin was 31617 bps in 2024 against a maximum downside of 31617 bps in 2024.
• Year by year, Operating Margin stood at 394.86% in 2021, then jumped by 100 bps to 1.13% in 2023, then slumped by 28077 bps to 317.29% in 2024.
• According to Business Quant data, Operating Margin over the past three periods registered 317.29%, 1.13%, and 394.86% for Q2 2024, Q2 2023, and Q4 2021 respectively.